Perfusion CT Scans for Kidney Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Chaan Ng, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is to learn if dynamic contrast enhanced computed tomography (DCE-CT) scans can help researchers learn if the study drug received as part of study 2010-0085 (either everolimus, bevacizumab, or pazopanib) is working.

Research Team

Chaan Ng, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults over 18 with metastatic renal cell carcinoma who are enrolled or considering enrollment in the START trial. They must have good kidney function, not be pregnant or breastfeeding, and can't join if they've had recent radiotherapy to the tumor area or are allergic to CT contrast media.

Inclusion Criteria

My kidney function is within the normal range.

I am 18 years old or older.

Patient must be enrolled or being considered for enrollment on protocol 2010-0085.

Exclusion Criteria

I am a woman who can have children and have a recent negative pregnancy test.

I am allergic to CT scan dye and need steroids before the scan.

I haven't had radiotherapy on the main cancer spot in the last 4 weeks.

Treatment Details

Interventions

• Perfusion CT scan (Diagnostic Imaging Agent)

Trial Overview The study tests whether a special type of CT scan called dynamic contrast enhanced computed tomography (DCE-CT) can determine how well treatments like everolimus, bevacizumab, or pazopanib are working in patients with advanced kidney cancer.

Participant Groups

Group I: DCE-CT Scans Experimental Treatment 1 Intervention

DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine